Enliven Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Enliven Therapeutics

28/07/2023 18:37

* Enliven Therapeutics Inc  ELVN.OQ   ELVN.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 1 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Enliven
Therapeutics Inc
is for a loss of 36 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enliven
Therapeutics Inc is $32​, above​ its last closing price
of $18.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.64       -0.63      -0.80     Missed  -26.3
  2023                                                  
 Sep. 30 2022  -1.00       -1.00      -0.72     Beat    28​
 Jun. 30 2022  -2.03       -2.05      -1.76     Beat    14.1
 ​​Mar.        -2.31       -2.31      -2.24     Beat    3.1
 31 2022                                                
 Dec. 31 2021  -3.16       -3.00      -2.12     Beat    29.4​
 Sep. 30 2021  -2.90       -3.38      -2.20     Beat    35
 Jun. 30 2021  -3.02       -3.20      -2.96     Beat    7.6
 This summary was machine generated July 28 at 17:37 GMT.  All
figures in US dollars  unless otherwise stated